Brief: Pharming Announces US FDA Acceptance Of Snda For Lower Doses Of Joenja
25/09/2026 15:36
BRIEF-Pharming Announces US FDA Acceptance Of Snda For Lower Doses Of Joenja Sept 25 (Reuters) - Pharming Group N.V. PHAR.AS:
PHARMING ANNOUNCES U.S. FDA ACCEPTANCE AND PRIORITY REVIEW OF SNDA FOR LOWER DOSES OF JOENJA® TO TREAT CHILDREN WITH APDS
PHARMING GROUP N.V. - APPLICATION GRANTED PRIORITY REVIEW WITH PDUFA DATE JANUARY 30, 2027
PHARMING GROUP N.V. - FDA ACCEPTS PHARMING'S SNDA FOR LOWER DOSES OF JOENJA
PHARMING GROUP N.V. - PDUFA TARGET ACTION DATE OF JANUARY 30, 2027
Source text: ID:nGNXbjjzWN
Further company coverage: PHAR.AS
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;;))